SLG
SGMO

Stanley-Laman Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Stanley-Laman Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-27,059
Closed -$291K – 278
2019
Q2 		$291K Hold
27,059
– – 0.07% 227
2019
Q1 		$258K Buy
+27,059
New +$276K 0.06% 233
2018
Q3 		– Sell
-107,548
Closed -$1.53M – 234
2018
Q2 		$1.53M Buy
+107,548
New +$1.79M 0.34% 86

Other funds holding SGMO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stanley-Laman Group's SGMO Position: Q3 2019 in Review

Stanley-Laman Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2019, closing a stake of 27,059 shares — an estimated $291K sold.

Stanley-Laman Group first reported a position in SGMO in Q2 2018 and held it in 3 quarters. The position peaked at $1.53M in Q2 2018. 184 funds tracked by Wall St. Rank hold SGMO as of Q3 2019.

  • Stanley-Laman Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2019 after selling out during the quarter.
  • Stanley-Laman Group sold 27,059 SANGAMO THERAPEUTICS INC shares in Q3 2019, an estimated $291K.
  • Stanley-Laman Group first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and held it in 3 quarters.
  • Stanley-Laman Group's SANGAMO THERAPEUTICS INC position peaked at $1.53M in Q2 2018.
  • 184 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2019.

Based on Stanley-Laman Group's 13F filing for Q3 2019, filed 8 Nov 2019.